Stroke Prevention through Plaque Stabilization
First and only carotid stent system designed and indicated for Transcarotid access
Designed with purpose
Designed for TCAR, the ENROUTE stent system provides excellent plaque stabilization without compromising conformability
- Ergonomic design – Short 57cm delivery system for safe and easy delivery
- Precise – Minimal foreshortening allows for precise and total lesion coverage
- Conformable – With its auto-tapering technology, the ENROUTE stent can conform to even the most difficult anatomies
See it’s effectiveness
Optimized hybrid-cell stent design auto-tapers in 2mm segments for uniform scaffolding that respects native vessel anatomy.
Superb Lesion Coverage
Micromesh geometry with each auto-tapering 2mm segment acting as its own stent to contour against plaque.
Instructions for use
The ENROUTE Transcarotid Stent System used in conjunction with the ENROUTE Transcarotid Neuroprotection System (NPS) is indicated for the treatment of patients at high risk for adverse events from carotid endarterectomy.
Discover our other products
ENROUTE® Transcarotid Neuroprotection System
Enables the reversal of blood during the TCAR procedure to protect the brain from potential emboli.
ENHANCE® Transcarotid Peripheral Access Kit
The only micropuncture access kit developed for the TCAR procedure making it easier, safer, and more efficient.
Provides precise lesion navigation in tortuous short vessel segments while performing TCAR.
Indications for Use: The ENROUTE® Transcarotid Stent System used in conjunction with the ENROUTE Transcarotid Neuroprotection System (NPS) is indicated for the treatment of patients at high risk for adverse events from carotid endarterectomy, who require carotid revascularization and meet the criteria outlined below.
- Patients with neurological symptoms and › 50% stenosis of the common or internal carotid artery by ultrasound or angiogram OR patients without neurological symptoms and › 80% stenosis of the common or internal carotid artery by ultrasound or angiogram, AND
- Patients must have a vessel diameter of 4-9 mm at the target lesion, AND
- Carotid bifurcation is located at minimum 5 cm above the clavicle to allow for placement of the ENROUTE Transcarotid NPS.
Please refer to Instructions for Use for indications, contraindications, warnings and precautions.
Caution: Federal (U.S.) law restricts this device to sale by or on the order of a physician.
Contraindications: Use of the ENROUTE Transcarotid Stent System is contraindicated in the following patients:
- Patients in whom antiplatelet and/or anticoagulation therapy is contraindicated.
- Patients in whom the ENROUTE Transcarotid NPS is unable to be placed.
- Patients with uncorrected bleeding disorders.
- Patients with known allergies to nitinol.
- Lesions in the ostium of the common carotid artery.
- Only physicians who have received appropriate training for transcarotid stenting and who are familiar with the principles, clinical applications, complications, side effects and hazards commonly associated with carotid interventional procedures should use this device.
- The safety and efficacy of the ENROUTE Transcarotid Stent System have not been demonstrated with embolic protection systems other than the ENROUTE Transcarotid NPS. Use the ENROUTE Transcarotid Stent System only with the ENROUTE Transcarotid NPS.
- The long term performance (> 3 years) of carotid stents has not yet been established.
- As with any type of vascular implant, infection secondary to contamination of the stent may lead to thrombosis, pseudoaneurysm or rupture.
- The stent may cause a thrombus, distal embolization or may migrate from the site of implant through the arterial lumen. Appropriate sizing of the stent to the vessel is required to reduce the possibility of stent migration (see Section 9.3 of these instructions). In the event of thrombosis of the expanded stent, thrombolysis and PTA should be attempted.
- Overstretching of the artery may result in rupture and life-threatening bleeding.
- In patients requiring the use of antacids and/or H2-antagonists before or immediately after stent placement, oral absorption of antiplatelet agents (e.g. aspirin) may be adversely affected.
- The appropriate antiplatelet and anticoagulation therapy should be administered pre- and post-procedure as suggested in Section 9.1 of these instructions.
- In the event of complications such as infection, pseudoaneurysm or fistulization, surgical removal of the stent may be required.
Non-clinical testing has demonstrated that the ENROUTE Transcarotid Stent is MR Conditional. A patient with this device can be scanned safely in an MR system meeting the following conditions:
– Static magnetic field of 1.5-Tesla or 3-Tesla, only
– Maximum spatial gradient magnetic field of 4,000 Gauss/cm (40 Tesla/m) or less
– Maximum MR system reported, whole body averaged specific absorption rate (SAR) of 2-W/kg (Normal Operating Mode).
Under the scan conditions defined above, the ENROUTE Transcarotid Stent is expected to produce a maximum temperature rise of 2.4°C after 15 minutes of continuous scanning.
In non-clinical testing, the image artifact caused by the device extends approximately 5 mm from the ENROUTE Transcarotid Stent when imaged with a gradient echo pulse sequence and a 3-Tesla MRI system. The artifact does obscure the device lumen.
Potential Adverse Events
Adverse Events (in alphabetical order) that may be associated with the use of the ENROUTE Transcarotid Stent System when used in conjunction with the ENROUTE Transcarotid NPS include, but may not be limited to (based upon clinical trial data for the PRECISE Stent System and the ANGIOGUARD XP Emboli Capture Guidewire and clinical trial data from the ROADSTER and PROOF studies):
Air embolism, Allergic/anaphylactoid reaction, Anemia, Aneurysm, Angina/coronary ischemia, Arrhythmia (including bradycardia, possibly requiring need for a temporary or permanent pacemaker), Arterial dissection, Arterial occlusion/restenosis of the treated vessel, Arterial occlusion/thrombus, at puncture site, Arterial occlusion/thrombus, remote from puncture site, Arteriovenous fistula, Atelectasis, Atrial Fibrillation, Bacteremia or septicemia, Cerebral edema, Congestive heart failure, Death, Embolization, arterial, Embolization, stent, Emergent repeat hospital intervention, Fever, Gastrointestinal disorders, GI bleeding from anticoagulation/antiplatelet medication, Hallucination, Hematoma bleed, access site, Hematoma bleed, remote site, Hemorrhage, Hyperperfusion syndrome, Hypotension/hypertension, Hypomagnesaemia, Hypophosphatemia, Infection, Intimal injury/dissection, Ischemia/infarction of tissue/organ, Local infection and pain at insertion site, Malposition (failure to deliver the stent to the intended site), Myocardial infarction, Nausea, Oxygen saturation decrease, Pain, Pseudoaneurysm, Rales, Renal failure, Respiratory Infection, Restenosis of the vessel (> 50% obstruction), Rhinorrhea, Seizure, Severe unilateral headache, Stent migration, Stent thrombosis, Stroke, Transient ischemic attack, Transient intolerance to reverse flow, Urinary tract infection, Vasospasm, Venous occlusion/thrombosis, at puncture site, Venous occlusion/thrombosis, remote from puncture site, Vessel rupture, dissection, perforation, Vomiting, Wheezing
Caution: Federal (U.S.) Law restricts this device to sale by or on the order of a physician. ENROUTE and the Silk Road Logo are registered trademarks of Silk Road Medical, Inc. CORDIS®, PRECISE® and ANGIOGUARD® are registered trademarks of Cordis Corporation.